This clinical trial sought to investigate if adding immunotherapy to standard chemo before surgery improves outcomes for patients with high-risk, early-stage triple-negative breast cancer. According to the Irish Cancer Society, about 1 in every 8³ breast cancers is triple negative. It also tends to be more common in younger women.

This clinical trial is testing whether adding a newer, targeted drug to a standard three-drug combination could produce stronger responses in patients with newly diagnosed myeloma who were eligible for a stem cell transplant.

Breast cancer for some relapsing patients / 2 patients (12 targeted)

This breast cancer trial aims to find out whether treatment with a new kind of endocrine therapy is effective for patients who have relapsed after surgery (or after surgery combined with chemotherapy or radiotherapy). To date two patients have been recruited, with 43 patients being screened for participation. 

Multiple myeloma is a type of blood cancer that, while treatable, currently cannot be cured, meaning most patients will eventually need new treatments as their cancer comes back or stops responding. This tested whether combining four medicines could help patients in this situation who had already tried at least two previous treatments. The study found that this combination was safe to use, with side effects that were manageable and similar to other existing treatments. 

According to the Irish Cancer Society, about 370⁴ people are diagnosed with multiple myeloma in Ireland every year, and it usually affects people over the age of 50.

This is a study for up to 136 prostate cancer patients that is trying to reduce the side effects that patients may experience, by using methods to reduce radiation dose to their healthy organs, while maintaining the high cancer cure rates. The trial will open in 11 centres all over the island of Ireland (i.e. in the Republic and NI). This trial will open in a matter of weeks.

This is a clinical trial for up to 144 men with metastatic prostate cancer that seeks to evaluate whether treating them with intermittent (rather than continuous) hormone therapy will reduce side effects and improve quality of life, without having a negative impact on survival rates. 

This trial was designed for men with prostate cancer that had spread to the bones and was no longer responding to standard hormone therapy. Two treatments that were already approved individually were tested together. Because the two drugs work in completely different ways, researchers hoped combining them might be more effective than either alone.

This study explored whether adding a drug to standard hormone treatment, given before radiotherapy begins, could improve outcomes for men at this earlier stage of the disease. Prostate cancer that hasn’t spread beyond the prostate is usually treated with a combination of hormone therapy and radiotherapy. The drug in this trial works by cutting off the supply of male hormones like testosterone that fuel cancer growth, and was already shown to help men with advanced prostate cancer. 

According to the Irish Cancer Society, about 4,000² men are diagnosed with prostate cancer each year in Ireland, meaning 1 in 6 men will be diagnosed with it during their lifetime.